Pharmacological chaperoning: two 'hits' are better than one

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Protein folding disorders are a growing class of diseases caused by proteins failing to achieve their correct 3D structure.
• Misfolded proteins can lead to aggregate accumulation, cell death, or degradation by cellular quality control.
• Current small molecule therapies often restore only a small fraction of proteins to their normal folding pathway.

Purpose of the Study:

• To investigate the potential of combination therapy for protein folding disorders.
• To evaluate the additive effects of multiple corrector molecules on mutant ABC transporters.

Main Methods:

• Studied mutant forms of ATP-Binding-Cassette (ABC) transporters, specifically P-glycoprotein and cystic fibrosis transmembrane conductance regulator (CFTR).
• Assessed the impact of single and multiple corrector molecules on protein trafficking and folding.

Main Results:

• Modest correction of trafficking defects by single agents was observed.
• The effects of multiple corrector molecules were additive, showing enhanced correction when used in combination.
• This additive effect was demonstrated for mutant P-glycoprotein and CFTR.

Conclusions:

• Combination therapy using multiple corrector molecules holds promise for treating protein folding disorders.
• Targeting different steps in the protein folding pathway with multiple agents may provide a synergistic therapeutic effect.
• This multidrug approach could be a viable strategy for improving patient outcomes in protein folding disorders.